Pemafibrate 18971 InChi: InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9

InChi: InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9

3-bromo-5-phenyl Salicylic Acid is a cell-permeable salicylic acid compound that acts as a highly potent

InChiKey: OMGLGPKQUFSRNN-UHFFFAOYSA-N

InChi: InChI=1S/C63H113N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27

Pemafibrate 18971 InChi: InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9Pemafibrate is a potent PPAR agonist, with EC50s of 1 nM, 1. 10 uM and 1. 58 uM for h PPAR, h PPAR and h PPAR, respectively, and possesses lipid lowering effect. Pemafibrate is a potent PPAR agonist, with EC50s of 1 nM, 1. 10 uM and 1. 58 uM for h PPAR, h PPAR and h PPAR, respectively. Pemafibrate is more than 1000 fold selective towards PPAR than PPAR and PPAR. Pemafibrate (3 mg kg, p. o.) increases plasma h apoA I in human apoA I (h apoA I)